

Hamilton et al - IL-6 signalling and risk of TB disease

Altered IL-6 signalling and risk of tuberculosis disease: a meta-analysis and Mendelian randomisation study

Fergus Hamilton¹, Haiko Schurz², Tom A. Yates⁸, James J. Gilchrist^{3,9}, Marlo Möller², Vivek Naranbhai^{3,4,5,6,7}, Peter Ghazal³⁵, Nicholas J Timpson¹, International Host TB Genetics Consortium*, Tom Parks^{3,10}, Gabriele Pollara⁸

*International Host TB Genetics Consortium authors

Peter J. Dodd¹¹, Eileen G Hoal², Andrew P. Morris¹², Adrian V.S. Hill^{3,13}, Reinout van Crevel^{14,15}, Arjan van Laarhoven¹⁴, Tom Ottenhoff¹⁶, Andres Metspalu¹⁷, Reedik Magi¹⁷, Christian G. Meyer¹⁸, Magda Ellis¹⁹, Thorsten Thye²⁰, Surakameth Mahasirimongkol²¹, Ekawat Pasomsu²², Katsushi Tokunaga²³, Yosuke Omae²³, Hideki Yanai²⁴, Taisei Mushiroda²⁵, Michiaki Kubo²⁵, Atsushi Takahashi^{26,27}, Yoichiro Kamatani²⁶, Bakti Alisjahbana²⁸, Wei Liu^{29,30}, A-dong Sheng^{31,32,33,34}, Yurong Yang³⁵

Affiliations

1. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
2. DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
3. Wellcome Trust Centre for Human Genetics, Oxford, UK
4. Massachusetts General Hospital, Boston, USA
5. Dana-Farber Cancer Institute, Boston, USA
6. Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
7. Harvard Medical School, Boston, USA
8. Division of Infection and Immunity, University College London, London, UK
9. Department of Paediatrics, University of Oxford, UK
10. Department of Infectious Diseases Imperial College London, London, UK
11. School of Health and Related Research, University of Sheffield, Sheffield, UK
12. Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK
13. Jenner Institute, University of Oxford, UK
14. Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands
14. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
15. Head Lab Dept of Infectious Diseases; Head Group Immunology and Immunogenetics of Bacterial Infectious Diseases Leiden University Medical Center, PO Box 9600, 2300RC Leiden, the Netherlands
16. Estonian Genome Center, Institute of Genomics, University of Tartu, Estonia
17. Institute of Tropical Medicine, Eberhard-Karls University Tübingen, Germany and Faculty of Medicine, Duy Tan University, Da Nang, Vietnam
18. Tuberculosis Research Group, Centenary Institute, Sydney, Australia
19. Department of Infectious Disease Epidemiology, Bernhard Nocht Institute for Tropical Medicine Hamburg, 20359 Hamburg, Germany
20. Department of Medical Sciences, Ministry of Public Health, Nonthaburi, 11000, Thailand
21. Virology Laboratory, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Hamilton et al - IL-6 signalling and risk of TB disease

22. Genome Medical Science Project, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan
23. Fukuji Hospital and Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Kiyose, 204-0022, Japan
24. RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, 230-0045, Japan
25. Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, 230-0045, Japan
26. Department of Genomic Medicine, Research Institute, National Cerebral and Cardiovascular Center, Suita, Osaka, 564-8565, Japan
27. Faculty of Medicine, Universitas Padjdjaran - Hasan Sadikin Hospital, Bandung Indonesia
28. Department of Plastic and reconstructive surgery, shanghai Key laboratory of Tissue engineering, shanghai Ninth People's hospital, shanghai Jiao Tong University – school of Medicine, shanghai, People's republic of China
29. National Tissue engineering center of China, shanghai, People's republic of China
30. National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics, Capital Medical University, No. 56 Nanlishi Road, Xicheng District, Beijing, 100045, China
31. Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, No. 56 Nanlishi Road, Xicheng District, Beijing, 100045, China
32. Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, No. 56 Nanlishi Road, Xicheng District, Beijing, 100045, China
33. Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China
34. Ningxia Medical University, Ningxia Hui Autonomous Region, the People's Republic of China
35. Cardiff University, Cardiff, UK

Corresponding author: Dr Fergus Hamilton, MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom, Email: fh6520@bristol.ac.uk

Running title: IL-6 signalling and risk of TB disease

Word count: 3638

Hamilton et al - IL-6 signalling and risk of TB disease

Summary

IL-6 responses are ubiquitous in *Mycobacterium tuberculosis* (*Mtb*) infections, but their role in determining human tuberculosis (TB) disease risk is unknown. We used single nucleotide polymorphisms (SNPs) in and near the IL-6 receptor (*IL6R*) gene, focusing on the non-synonymous variant, rs2228145, associated with reduced classical IL-6 signalling, to assess the effect of altered IL-6 activity on TB disease risk. We identified 16 genome wide association studies (GWAS) of TB disease collating 17,982 cases of TB disease and 972,389 controls across 4 continents. Meta-analyses and Mendelian randomisation analyses revealed that reduced classical IL-6 signalling was associated with lower odds of TB disease, a finding replicated using multiple, independent SNP instruments and 2 separate exposure variables. Our findings establish a causal relationship between IL-6 signalling and the outcome of *Mtb* infection, suggesting IL-6 antagonists do not increase the risk of TB disease and should be investigated as adjuncts in treatment.

Summary word count = 148

Keywords: Tuberculosis, IL-6 receptor, meta-analysis, Mendelian randomisation

Hamilton et al - IL-6 signalling and risk of TB disease

Introduction

Up to a quarter of the world's population shows evidence of exposure to *Mycobacterium tuberculosis* (*Mtb*) infection. Whilst only a small proportion of these individuals develop symptomatic tuberculosis (TB) disease, this translated to 10.6 million new cases and 1.6 million deaths worldwide in 2021.^{1,2} Immune responses to *Mtb* infection can determine clinical outcomes and involve multiple cellular and cytokine components with the use of IL-6 inhibitors (e.g. tocilizumab) thought to predispose to TB disease^{3,4}. Contemporary clinical guidelines (e.g. American College of Rheumatology,⁵ British Society of Rheumatology⁶) and regulators (e.g. Food and Drug Administration⁷, Medicine and Health Regulatory Authority⁴) recommend screening patients for latent TB infection prior to starting tocilizumab. However, the role of this pathway in the host response to *Mtb* infection remains uncertain.^{8,9}

In mice, despite promoting early Th1 responses, IL-6 is not essential for protection against *Mtb* infection^{10,11}. In humans, registries of patients receiving IL-6 antagonists have not identified an elevated risk of incident TB disease.¹² In contrast, elevated expression of plasma IL-6 cytokine and expression of an IL-6 response transcriptional signature are associated with more severe TB disease.^{13,14} Furthermore, elevated IL-6 responses are observed in patients with TB disease compared to healthy controls both at the site of *in vivo* standardised mycobacterial antigen challenge and in *ex vivo* stimulated monocytes.¹⁵ This increased IL-6 activity was accompanied by greater recruitment of Th17 cells and neutrophils, cells associated with tissue pathology.¹⁵ Elevated IL-6 responses in pulmonary TB are also associated with post-treatment lung impairment.¹⁶ However, whether, exaggerated IL-6 responses in people with active TB are the cause or consequence of greater tissue damage and disease severity remains unclear.

IL-6 exerts all its biological effects through binding the IL-6 receptor (IL6R) which exists in both membrane bound and soluble forms.¹⁷ Genetic variants in *IL6R*, which code for IL6R, associate with altered IL-6 signalling. One particular variant, rs2228145 (also known as Asp358Ala) is well-established as the major genetic determinant of IL6R levels, explaining 20-40% of observed variance.^{18,19} The minor allele (C) has a frequency of around 10% in African populations but up to 40% in other populations, such as in Europeans.¹⁸ The C allele is associated with alternative splicing of IL6R and increased proteolytic cleavage by ADAM17 of the membrane-bound form of IL6R, leading to an increase in soluble IL6R. The net effect of these changes is a reduction in classical (*cis*) IL-6 signalling activity and circulating levels of C-reactive protein (CRP).¹⁹⁻²¹ rs2228145-C is associated with reduced odds of developing several inflammatory conditions, including rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).²² Leveraging the fact that the C allele of rs2228145 mimics (i.e. phenocopies) pharmacologic IL-6 inhibition, Mendelian randomisation (MR) analyses predicted that tocilizumab would be an effective treatment for COVID-19²³⁻²⁵ and improve cardiometabolic

Hamilton et al - IL-6 signalling and risk of TB disease

biomarkers in patients with high cardiovascular risk, as subsequently demonstrated in randomised controlled trials.^{26,27}

In this study, we tested the hypothesis that IL-6 signalling affects the risk of developing TB disease by using genetic variation in *IL6R* as an instrumental variable in MR analyses. The available datasets allowed us to perform this analysis in several geographically diverse human populations.

STAR Methods

Study design

We performed a meta-analysis of genome wide association studies (GWAS) assessing host genetic susceptibility to TB disease. From these studies, we extracted the associations between variants *cis* to (within 300kb of) *IL6R* associated with IL-6 signalling and TB disease. We used these summary statistics in two sample MR analyses to estimate the causal effect of reduced IL-6 signalling on TB disease.

Identification of GWAS and data extraction

Our inclusion criteria included all publicly available GWAS for which TB disease was an outcome, and that included the rs2228145 SNP (or SNPs in close linkage disequilibrium, $R^2 > 0.9$), accepting the definition of TB used in the primary study (Table 1). We included both case-control and cohort studies, the largest of which was a multi-ancestry, GWAS meta-analysis which included 12 GWAS across diverse populations.²⁸ We extracted associations from both the full meta-analysis, which was performed using MR-MEGA and GWAMA^{29,30} and each individual study. Additionally, we screened the European Bioinformatics Institute (EBI) and MRC-IEU GWAS catalogues for all GWAS on TB to identify others with publicly available summary statistics. We also searched the MEDLINE database using the terms “tuberculosis” AND “GWAS” OR “Genome wide association study”. Finally, for all included studies, we reviewed both the papers they cited and, using Google Scholar, the papers that cited them. Alongside the summary statistics, data were extracted on demographics, TB disease prevalence, TB case definitions, and methodology. Where multiple GWAS on the same population were available (e.g. UK Biobank), the most recent was used.

These searches identified 4 further relevant studies that had publicly available summary statistics: 3 cohort studies, UK Biobank (UKB)³¹, FinnGen (FG)³², and Biobank Japan (BBJ)³³ and one case control study in China³⁴ not included in the Schurz et al meta-analysis (Table 1). Other studies were identified but summary statistics were not available.³⁵⁻³⁷ Additionally, one GWAS was performed in HIV seropositive individuals, with no summary statistics available, one GWAS was performed on early progression to TB disease and so was excluded, and one GWAS merged both latent and active tuberculosis individuals, and so was also excluded.³⁸⁻⁴⁰ For UKB, TB was defined via self-report of diagnosis, and multiple GWAS have been

Hamilton et al - IL-6 signalling and risk of TB disease

performed by multiple groups. We chose the most recent GWAS performed by the Pan-UK Biobank team in European ancestry participants as this was performed using SAIGE⁴¹, which accounts for extreme case control imbalance well. In FinnGen, TB was defined using ICD-10 coding from Electronic Health Record data. Three definitions of TB were extracted – any form of TB (ICD codes A15-19), pulmonary TB (A15 or A16), and pulmonary TB with bacteriological or histological confirmation (A15 only). As we were aiming for specificity, we utilised the most specific code (A15) for downstream meta-analysis. In Biobank Japan, pulmonary TB was identified using ICD coding (ICD A15 or A16) as this was the only code available. For the study performed in China³⁴, TB cases were defined using clinical and microbiological definitions (Table 1).

Extraction of SNPs and definition of exposure

For all GWAS, we extracted effect estimates, standard errors, and allele frequencies for the rs2228145 SNP.⁴² Additionally, we extracted effect estimates for SNPs within 300kb of *IL6R*, for use in secondary analyses, described below.

Primary analysis: CRP as instrument variable

For all studies, we performed a meta-analysis of the effect of rs2228145 on the odds of TB disease. As we only had access to GWAS summary statistics, an additive model was used, and effects were calculated per each additional C allele. Meta-analysis was performed using inverse-variance weighting (IVW) using the *meta* package in R.⁴³ Heterogeneity was assessed using I^2 . Fixed effects models are reported throughout the text, although we also report random effects models in the main analysis for comparison.

MR was performed using the rs2228145 SNP as an instrument to assess the effect of reduced classical IL-6 signalling on the risk of TB disease. Our exposure was defined as reduced IL-6 signalling, as measured by the effect of this SNP on plasma CRP levels. We used estimates derived from a meta-analysis of GWAS performed in individuals from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium and UK Biobank.^{21,44} CRP as a proxy for classical IL-6 signalling has been widely used in MR studies at this locus as a phenocopy for IL-6 receptor inhibition, as CRP is produced in hepatocytes in direct response to IL-6 signalling, and variants *cis* to *IL6R* are highly likely to affect CRP by altering *IL6R* activity/and or function.^{8,21,45,46} The rs2228145-C allele stoichiometrically increases soluble *IL6R* relative to its membrane bound at both the baseline level form through differential splicing, as well as by increased efficiency of ADAM17 proteolytic cleavage of the membrane bound form in inflammation. This reduced classical signalling can potentially increase “trans” IL-6 signalling,^{19–21} and therefore this allele changes the set point of *IL6*-signalling but does not strictly downregulate the IL-6 pathway. However, the similarity with pharmacologic IL-6 antagonism in certain inflammatory disease contexts supports the notion that this SNP contributes towards moderated IL-6 pathway activity.^{17,19,26}

Hamilton et al - IL-6 signalling and risk of TB disease

MR estimates for rs2228145 were generated by the Wald ratio, and were meta-analysed using an IVW approach, as above.⁴⁷ In line with other recent studies, we present results weighted on CRP reductions, so odds ratios (ORs) of less than one represent reduced odds of TB disease with less IL-6 signalling.

Additional analyses: IL6R protein as instrument variable

For all studies performed on populations of European and African ancestry, we were able to perform additional analyses, using multiple SNPs cis to *IL6R* as an instrument for IL6R plasma protein levels to increase statistical power. Plasma protein levels of IL6R inversely correlate with CRP, reflecting a decrease in classical signalling, and have been used to instrument IL-6 signalling in MR studies before⁴⁸⁻⁵⁰. Additionally, matched instruments were available for both European and African ancestry participants, using a recent GWAS from the ARIC consortium.¹⁸ This GWAS (n ~ 1,500), performed in African Americans and European Americans (independently), remains the only available GWAS data on plasma protein levels in African ancestry participants.

Independent ($r^2 < 0.1$) SNPs with $p < 5 \times 10^{-8}$ within 300kb of *IL6R* were extracted from both GWAS of IL6R levels performed in ARIC and used as instruments in MR independently for European and African ancestry cohorts. To ensure these SNPs had an effect on IL-6 signalling, we identified their association with high sensitivity CRP from a large recent meta-analysis⁴⁴, and only included SNPs that had an opposing effect on CRP and IL6R (e.g. SNPs that increased IL6R and decreased CRP, or vice versa). MR estimates for each SNP were combined using IVW as our primary analytic method. For studies in Asia, we did not include any SNPs outside rs2228145 as there are no large scale GWAS of IL6R plasma protein to identify instruments. In these studies, we weighted rs2228145 by the effect on IL6R plasma protein generated in Europe, as there is little evidence of heterogeneity of effect at this exact SNP (beta in Europe 1.04, SE = 0.01); beta in Africa 1.21, SE = 0.04 per C allele), and prior data has shown similar effects of this SNP on IL-6 signalling regardless of ancestry.⁵⁰ As sensitivity analyses, we performed other meta-analytic approaches (e.g. weighted median, MR Egger) and performed leave-one out analyses, focusing on the removal of rs2228145, to determine whether results were robust to removal of this SNP.

Assumptions of MR

MR has 3 cardinal assumptions: relevance (that the instrument is associated with the exposure), independence (that there are no unmeasured confounders of the instrument and outcome association), and exclusion restriction (that the instrument only affects the outcome through the exposure). The relevance assumption is met in our analysis. The other two assumptions are unfalsifiable, although our sensitivity analyses (above) interrogate some of these assumptions.

Hamilton et al - IL-6 signalling and risk of TB disease

The potential for confounding and horizontal pleiotropy will vary according to the outcome of interest, but these variants have been used successfully in MR studies of other infectious and inflammatory conditions, with MR results mirroring the results of subsequent RCTs.^{19,26,46,51}

Data availability

Summary data are available at the author's GitHub (github.com/gushamilton/tb_il6r), allowing independent replication of all analyses reported.

Results

Study identification

From the meta-analysis by the International TB Host Genetics Consortium, we identified 12 GWAS that included rs2228145.²⁸ Details of these studies have already been described but are summarised in Table 1. All were case-control studies. Four were performed in Africa,^{28,52-54} 5 in Asia,^{55,56} and 3 in Europe.⁵⁷ Case definitions used in each study can be found in the original manuscript,²⁸ but this included microbiological confirmation for most studies (9/12), except in Estonia, which was a Biobank study.

We identified 4 further relevant studies that had publicly available summary statistics: 3 cohort studies (UK Biobank (UKB)³¹, FinnGen (FG)³², and Biobank Japan (BBJ)³³) and one case control study in China³⁴ not included in the Schurz et al meta-analysis (Table 1). The three Biobank studies used ICD coding, while the Chinese study used microbiological confirmation to define cases of TB disease.

Association between IL6R rs2228145-C allele and TB disease

We performed a meta-analysis across the 16 available studies, which included 18,165 cases of tuberculosis and 976,727 controls. The C allele of rs2228145 was associated with decreased risk of tuberculosis disease, with a summary odds ratio (OR) of 0.94, 95% CI 0.91 – 0.97, $p = 2.92 \times 10^{-5}$, per each additional C allele (Table 2). There was weak evidence of heterogeneity across studies ($I^2 = 0.315$, $p = 0.11$). Effect estimates were similar in random effects analyses, although precision was reduced (OR 0.95; 95% CI 0.91 – 0.98, $p = 0.009$).

Next we performed MR using the rs2228145 SNP to quantify the effect of altered IL-6 signalling activity on the risk of TB disease, proxied by CRP levels. MR analyses were undertaken separately for each of the TB GWAS then pooled using fixed effects meta-analysis, yielding an OR of 0.50 (95% CI 0.39 - 0.71, $p = 2.9 \times 10^{-5}$) for each natural log CRP decrease, indicating that reduced classical IL-6 activity was associated with lower risk of TB disease development (Fig 1 & Table S1)

Hamilton et al - IL-6 signalling and risk of TB disease

Association between other IL6R SNPs and TB disease

To explore the association between TB disease risk and IL-6 signalling outside rs2228145, we used alternative instrumental variables. Although rs2228145 is known to affect CRP in African ancestry populations^{42,50} there are no large scale GWAS of CRP in African ancestry populations, meaning no other SNPs can be used as instrumental variables for CRP. Therefore, we chose to use plasma concentration of IL6R protein itself as an exposure, as has been done in other MR studies at this locus.⁴⁸ We identified independent ($r^2 < 0.1$) SNPs (5 in African Americans (AA), and 34 in European Americans (EA)) within 300kb of *IL6R* associated with IL6R plasma protein levels in the Atherosclerosis Risk in Communities GWAS (Table S2).¹⁸ To ensure these SNPs affected downstream IL-6 signalling, proxied by altered CRP concentrations, we plotted the effect of each SNP on both IL6R protein and CRP, from a large GWAS meta-analysis.⁴⁴ As expected, there was a strong negative correlation between CRP and IL6R protein ($r = -0.80$ in EA, $R = -0.97$ in AA, figure S1A&B). Only 5 SNPs were directionally inconsistent (all in European populations), and these were removed, leaving 29 to take forward to MR analyses.

Using these 29 SNPs¹⁸, we undertook MR analyses describing the association between plasma IL6R levels and TB disease. These analyses used data from 9 TB GWAS, all from Europe or Africa. We were unable to undertake these analyses in data from Asian GWAS, as there are no large scale GWAS of IL6R plasma protein levels available in Asian populations. These estimates using multiple SNP instruments were highly concordant with those using the single SNP rs2228145 (figure S1C), with greater precision achieved using 29 SNPs than when using rs2228145 alone.

Next, we calculated the effect of IL6R plasma protein levels on TB disease, with effect estimates from these 9 studies being derived from multiple SNPs and the remaining 7 studies from Asia (Figure 1) providing effect estimates from rs2228145 alone. As we do not have specific GWAS of IL6R in Asia, we used the effect estimates from European ancestries here, as prior data suggests little heterogeneity in effect estimates on IL-6 signalling at this specific SNP.⁵⁰ We subsequently meta-analysed all studies by fixed effects inverse variance weighting meta-analysis. This indicated that increased levels of IL6R plasma protein, a proxy for reduced classical IL-6 signalling¹⁹, are associated with reduced odds of TB disease (OR 0.95; 95% CI 0.93-0.97, $p = 4.15 \times 10^{-6}$). Using rs2228145 alone yielded concordant estimates (OR 0.96; 95% CI 0.91-0.97, $p = 2.92 \times 10^{-5}$), although the use of multiple SNPs increased statistical power exemplified by a smaller p value. Full results for both models are reported in Table S3.

Sensitivity analyses

For the 9 studies where multiple SNPs were available, we performed sensitivity analyses of the effect of IL6R plasma protein levels on odds of TB disease using different meta-analytic approaches (MR-Egger, Weighted median), which generated comparable results to those from our primary analyses using IVW

Hamilton et al - IL-6 signalling and risk of TB disease

(Table S4). Finally, we repeated our MR analyses describing the effect of IL6R plasma protein levels on odds of TB disease both with and without rs2228145, as this is by far the most powerful SNP. This showed comparable MR estimates from each study, although estimates lacking rs2228145 SNP were more imprecise (Figure S2).

Discussion

To determine the role of the IL-6 pathway in human *Mtb* infection, we performed a meta-analysis of the association between genetic variation at the *IL6R* locus and odds of TB disease in 18,165 cases of tuberculosis and 976,727 controls across 16 GWAS in African, Asian and European populations. We found the C allele of the *IL6R* SNP rs2228145, which mimics the effect of IL-6 antagonists such as tocilizumab, to be associated with lower odds of TB disease. MR using both this single and other neighbouring *IL6R* SNPs as instruments supports an overarching conclusion that reduced classical IL-6 signalling is causally associated with lower risk of active TB disease.

Our study challenges current guidance indicating IL-6 inhibition confers TB disease risk. Although prospective patient registries have not identified an association between use of IL-6 antagonists and *Mtb* reactivation^{3,12}, screening and treatment for latent *Mtb* infection remains recommended prior to commencement of these agents.⁴⁻⁷ The impact of such guidance is significant, including delayed initiation of biologic therapy and adverse effects of antibiotics for latent TB. Our findings indicate these concerns are unfounded, in contrast to the risk of pyogenic infections following IL-6 antagonism.^{46,58}

Furthermore, our analyses indicated that lower classical IL-6 signalling may be associated with lower risk of TB disease. Strikingly, the relationship between TB and *IL6R* variants resembles that observed in the chronic inflammatory disease RA, in which the *IL6R* rs2228145 C allele is also protective, and phenocopies the therapeutic benefit of drugs inhibiting IL6R activity *in vivo*.¹⁵ IL-6 promotes bacterial growth and monocyte expansion following human *Mtb* infection of hematopoietic stem cells, and activity of this cytokine in blood is associated with more extensive TB disease.¹³ Tissue IL-6 activity in TB disease is associated with radiological severity and impaired lung function,^{14,16} and the activity of this cytokine can drive pathology by promoting Th17 differentiation, IL-17 activity and neutrophil chemotaxis.¹⁷ Indeed, this specific constellation of immune responses is elevated in TB patients compared to latent or cured TB controls following standardised *in vivo* antigen challenge.¹⁵ A unifying hypothesis from these observations is that exaggerated IL-6 responses associated with non-resolving *Mtb* infection increase the risk of symptomatic TB disease by promoting pathological responses, and would be consistent with the directionality of effect we observed with altered IL-6 signalling and TB disease risk.

Hamilton et al - IL-6 signalling and risk of TB disease

The biology of IL-6 is complex, with both classical and trans signalling associated with disease risk.¹⁷ Our interpretation of the MR analyses necessitated the assumption that the rs2228145 SNP and other *cis* *IL6R* SNPs represent a proxy for decreased IL-6 signalling. The inverse relationship between plasma levels of CRP and IL6R is well recognised^{8,50} and all the SNPs used as instruments in this analysis associate with decreased CRP, supporting an association with an altered homeostasis set point that decreases classical IL-6 signalling. It is harder to comment on the effect of these instruments on trans signalling, given the absence of a simple biological readout for this pathway. Nevertheless, rs2228145 (and related SNPs) are still widely and successfully used as phenocopies for pharmacologic IL-6 antagonism^{19,26,27}, suggesting that instrumentation of the classical signalling pathway alone allows for causal inference from these SNPs into the potential effect of IL-6 signalling on TB disease risk.

Key strengths of our study were the large and diverse patient population included alongside the robustness of the genotype association with TB disease risk using multiple *cis* *IL6R* SNPs. Limitations included variability in the definition of a TB case, although microbiological confirmation of *Mtb* infection alongside symptoms was a criterion for confirming TB disease cases in almost all studies included. In addition, the protective effect of the rs2228145-C allele showed some evidence of heterogeneity, with effect estimates smaller and/or reversed in some populations. Differences in TB case definitions, infecting *Mtb* strains, study design and the extent to which cases and controls are exposed to *Mtb* may all confound an apparent ancestry-specific effect. In addition, the low allele frequency of rs2228145-C in the African ancestry populations make effect estimates imprecise. Apparent heterogeneity may simply represent the play of chance, given ancestry specific heterogeneity in complex traits is rare.⁵⁹ It is also noteworthy that MR estimates predict the effects of a lifetime of enhanced or reduced IL-6 signalling on risk of TB disease, which may qualitatively differ from the effects of short-term IL-6 antagonism^{60,61}. Although our exposure reflects a homeostasis set point change in IL-6 activity, mechanistically rs2228145-C should impact IL-6 signalling following *Mtb* exposure and MR studies using the same instrumental variable have predicted the outcome of RCTs following IL-6 blockade both in acute infection and established chronic inflammation.^{5,23,27} Finally, a TB diagnosis requires *Mtb* exposure, followed by establishment of infection that progresses to clinically apparent disease, and our data are not able to define the stage along this timeline that reduced IL-6 activity may protect from TB disease.

Conclusions

We found genetic evidence for a causal, protective effect of reduced IL-6 signalling in the development of TB disease, observations that should diminish concerns that IL-6 blockade enhances TB disease risk. Dissecting out the precise role of IL-6 in this complex host-pathogen interaction, including the impact of TB epidemiology and host genetic background, and a possible role for IL-6 mediating pathology will require

Hamilton et al - IL-6 signalling and risk of TB disease

mechanistic studies involving both *in vitro* cellular models and *in vivo* human experimental medicine approaches to identify any therapeutic role for adjunctive IL-6 antagonism in human TB disease.

Acknowledgments

FH's time was funded by the GW4 CAT Doctoral Fellowship scheme (Wellcome Trust, 222894/Z/21/Z). PG's time was funded by the Welsh Government and the EU-ERDF (Ser Cymru Scheme This work was also supported by funding from National Institute for Health Research (NIHR) (TAY, JYG, TP). NJT is a Wellcome Trust Investigator (202802/Z/16/Z) and works within the University of Bristol National Institute for Health Research (NIHR) Biomedical Research Centre (BRC). NJT is supported by the Cancer Research UK (CRUK) Integrative Cancer Epidemiology Programme (C18281/A29019). PJD was supported by a fellowship from the UK Medical Research Council (MR/P022081/1); this UK funded award is part of the EDCTP2 program supported by the European Union. ME was supported by an NHMRC fellowship (552496). The research was supported by the NHMRC grant 1025166. AvL and RvC are supported by the National Institute of Allergy and Infectious Diseases at NIH [R01 AI136921]. AM and RM are funded by the EU project no. 2014-2020.4.01.15-0012 "Gentransmed". BA is supported by the 'Scientific Programme Indonesia Netherlands' (SPIN) under the Royal Academy of Arts and Sciences (KNAW), the Netherlands. TP was funded by the Wellcome Trust 222098/Z/20/Z). GP's time was funded by the UCLH NIHR Biomedical Research Centre. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

Author contributions

Study conception, design, and oversight, FH, TP and GP; data acquisition, FH, HS, TAY, JYG, MM, VN, TP; data analysis and interpretation, FH, HS, TP, GP; manuscript composition and drafting FH, TAY, TP and GP. All authors reviewed and approved the final version of this manuscript.

Ethics statement

This study makes use of publicly available summary genetic association data which are available from peer reviewed publications or from the preprint of the ITHGC.²⁸ All institutions involved in the ITHGC have ethics approval for their respective studies: China 1 and 2: The study protocol was approved by the Ethics Committee of the Beijing Chest Hospital, the 309 Hospital of the PLA, Shijiazhuang Fifth Hospital, the China PLA General Hospital, the Tongliao TB institute and the Center for Diseases Control and Prevention in Jalainuoer. China 3: Ethics approval was granted by the Ethics Committees of the Beijing Childrens Hospital,

Hamilton et al - IL-6 signalling and risk of TB disease

the Beijing Geriatric Hospital, the Tuberculosis Hospital in Shaanxi Province, the Beijing Institute of Genomics, Chinese Academy of Sciences and the Center for Disease Control and Prevention of Jiangsu Province. Thailand: Ethics approval was granted by the Ethics Review Committee of the Ministry of Public Health in Thailand. Japan: Ethics approval was granted by the Institutional Review Board of the Center for Genomic Medicine, RIKEN. Russia: Blood samples from all participants were collected and studied with written informed consent according to the Declaration of Helsinki and with approvals from the local ethics committees in Russia (St. Petersburg and Samara) and the UK (Human Biological Resource Ethics Committee of the University of Cambridge and the National Research Ethics Service, Cambridgeshire 1 REC, 10/H0304/71). Estonia: The Estonian Bioethics and Human Research Council (EBIN) approved the Estonian Genome Center study reported in this manuscript. Germany: The study protocol was approved by the ethics committee (EC) of the University of Luebeck, Germany (reference 07/125), and was adopted by other ethics committees covering all 18 participating centres (EC of the medical faculty of the University of Goettingen; EC of the Medical Council of Hessen, Frankfurt /Main; EC of the Medical Council Hamburg; EC of the Medical Council Lower Saxony, Hannover; EC of the Medical Faculty Carl Gustav Carus, Technical University of Dresden; EC of the Medical Council Berlin; EC of the Medical Council Bavaria, Munich; EC of the Medical Faculty, Friedrich Alexander University Erlangen Nuremberg; EC of the Medical Faculty of the University of Regensburg; EC of the University of Witten/ Herdecke). Gambia: Ethics approval was granted by the Medical Research Council (MRC) and the Gambian government joint ethical committee. Ghana: Ethics approval was granted by the Committee on Human Research, Publications and Ethics, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, and the Ethics Committee of the Ghana Health Service, Accra, Ghana. SAC A and SAC M: Ethics approval was granted by the Health Research Ethics Committee of Stellenbosch University (project registration numbers S17/01/013, NO6/07/132 and 95/072).

Hamilton et al - IL-6 signalling and risk of TB disease

References

1. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. *PLoS Med* [Internet] 2016;13(10):e1002152. Available from: <http://dx.doi.org/10.1371/journal.pmed.1002152>
2. Programme GT. Global tuberculosis report 2022 [Internet]. 2022 [cited 2023 Jan 20]; Available from: <https://www.who.int/publications/i/item/9789240061729>
3. Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. *Clin Microbiol Rev* [Internet] 2020;33(3). Available from: <http://dx.doi.org/10.1128/CMR.00035-19>
4. Tocilizumab [Internet]. [cited 2022 Nov 25]; Available from: <https://bnf.nice.org.uk/drugs/tocilizumab/>
5. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol* [Internet] 2016;68(1):1–26. Available from: <http://dx.doi.org/10.1002/art.39480>
6. Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. *Rheumatology* [Internet] 2019;58(2):e3–42. Available from: <http://dx.doi.org/10.1093/rheumatology/key208>
7. Food and Drug Administration. Tocilizumab (ACTEMRA). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf
8. Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. *Nat Rev Rheumatol* [Internet] 2017;13(7):399–409. Available from: <http://dx.doi.org/10.1038/nrrheum.2017.83>
9. Ritter K, Rousseau J, Hölscher C. The Role of gp130 Cytokines in Tuberculosis. *Cells* [Internet] 2020;9(12). Available from: <http://dx.doi.org/10.3390/cells9122695>
10. Saunders BM, Frank AA, Orme IM, Cooper AM. Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to *Mycobacterium tuberculosis* infection. *Infect Immun* [Internet] 2000;68(6):3322–6. Available from: <http://dx.doi.org/10.1128/IAI.68.6.3322-3326.2000>
11. Sodenkamp J, Waetzig GH, Scheller J, et al. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. *Immunobiology* [Internet] 2012;217(10):996–1004. Available from: <http://dx.doi.org/10.1016/j.imbio.2012.01.015>

Hamilton et al - IL-6 signalling and risk of TB disease

12. Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. *Ann Rheum Dis* [Internet] 2013;72(4):482–92. Available from: <http://dx.doi.org/10.1136/annrheumdis-2012-202469>
13. Delgobo M, Mendes DA, Kozlova E, et al. An evolutionary recent IFN/IL-6/CEBP axis is linked to monocyte expansion and tuberculosis severity in humans. *Elife* [Internet] 2019;8. Available from: <http://dx.doi.org/10.7554/eLife.47013>
14. Losada PX, Perdomo-Celis F, Castro M, et al. Locally-secreted interleukin-6 is related with radiological severity in smear-negative pulmonary tuberculosis. *Cytokine* [Internet] 2020;127:154950. Available from: <http://dx.doi.org/10.1016/j.cyto.2019.154950>
15. Pollara G, Turner CT, Rosenheim J, et al. Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease. *Sci Transl Med* [Internet] 2021;13(592). Available from: <http://dx.doi.org/10.1126/scitranslmed.abg7673>
16. Gupte AN, Selvaraju S, Gaikwad S, et al. Higher interleukin-6 levels and changes in transforming growth factor- β are associated with lung impairment in pulmonary tuberculosis. *ERJ Open Res* [Internet] 2021;7(1). Available from: <http://dx.doi.org/10.1183/23120541.00390-2020>
17. Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. *Nat Rev Rheumatol* [Internet] 2020;16(6):335–45. Available from: <http://dx.doi.org/10.1038/s41584-020-0419-z>
18. Zhang J, Dutta D, Köttgen A, et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. *Nat Genet* [Internet] 2022;54(5):593–602. Available from: <http://dx.doi.org/10.1038/s41588-022-01051-w>
19. Ferreira RC, Freitag DF, Cutler AJ, et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. *PLoS Genet* [Internet] 2013;9(4):e1003444. Available from: <http://dx.doi.org/10.1371/journal.pgen.1003444>
20. Rose-John S. Interleukin-6 Family Cytokines. *Cold Spring Harb Perspect Biol* [Internet] 2018;10(2). Available from: <http://dx.doi.org/10.1101/cshperspect.a028415>
21. Georgakis MK, Malik R, Burgess S, Dichgans M. Additive Effects of Genetic Interleukin-6 Signaling Downregulation and Low-Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2x2 Factorial Mendelian Randomization Analysis. *J Am Heart Assoc* [Internet] 2022;11(1):e023277. Available from: <http://dx.doi.org/10.1161/JAHA.121.023277>

Hamilton et al - IL-6 signalling and risk of TB disease

22. Zhang M, Bai Y, Wang Y, et al. Cumulative Evidence for Associations Between Genetic Variants in Interleukin 6 Receptor Gene and Human Diseases and Phenotypes. *Front Immunol* [Internet] 2022;13:860703. Available from: <http://dx.doi.org/10.3389/fimmu.2022.860703>
23. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. *JAMA* [Internet] 2021;326(6):499–518. Available from: <http://dx.doi.org/10.1001/jama.2021.11330>
24. Larsson SC, Burgess S, Gill D. Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia. *Eur Respir J* [Internet] 2021;57(1). Available from: <http://dx.doi.org/10.1183/13993003.03545-2020>
25. Bovijn J, Lindgren CM, Holmes MV. Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19. *Lancet Rheumatol* [Internet] 2020;2(11):e658–9. Available from: [http://dx.doi.org/10.1016/S2665-9913\(20\)30345-3](http://dx.doi.org/10.1016/S2665-9913(20)30345-3)
26. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet* [Internet] 2012;379(9822):1214–24. Available from: [http://dx.doi.org/10.1016/S0140-6736\(12\)60110-X](http://dx.doi.org/10.1016/S0140-6736(12)60110-X)
27. Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet* [Internet] 2021;397(10289):2060–9. Available from: [http://dx.doi.org/10.1016/S0140-6736\(21\)00520-1](http://dx.doi.org/10.1016/S0140-6736(21)00520-1)
28. The International Tuberculosis Host Genetics Consortium, Schurz H, Naranbhai V, et al. Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture [Internet]. *medRxiv*. 2022 [cited 2022 Sep 12];2022.08.26.22279009. Available from: <https://www.medrxiv.org/content/10.1101/2022.08.26.22279009v1.abstract>
29. Mägi R, Horikoshi M, Sofer T, et al. Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. *Hum Mol Genet* [Internet] 2017;26(18):3639–50. Available from: <http://dx.doi.org/10.1093/hmg/ddx280>
30. Mägi R, Morris AP. GWAMA: software for genome-wide association meta-analysis. *BMC Bioinformatics* [Internet] 2010;11:288. Available from: <http://dx.doi.org/10.1186/1471-2105-11-288>
31. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* [Internet] 2018;562(7726):203–9. Available from: <http://dx.doi.org/10.1038/s41586-018-0579-z>

Hamilton et al - IL-6 signalling and risk of TB disease

32. Kurki MI, Karjalainen J, Palta P, et al. FinnGen: Unique genetic insights from combining isolated population and national health register data [Internet]. bioRxiv. 2022 [cited 2022 Apr 7];2022.03.03.22271360. Available from: <https://www.medrxiv.org/content/10.1101/2022.03.03.22271360v1.abstract>
33. Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet* [Internet] 2021 [cited 2022 Aug 23];53(10):1415–24. Available from: <http://dx.doi.org/10.1038/s41588-021-00931-x>
34. Zheng R, Li Z, He F, et al. Genome-wide association study identifies two risk loci for tuberculosis in Han Chinese. *Nat Commun* [Internet] 2018;9(1):4072. Available from: <http://dx.doi.org/10.1038/s41467-018-06539-w>
35. Hong EP, Go MJ, Kim H-L, Park JW. Risk prediction of pulmonary tuberculosis using genetic and conventional risk factors in adult Korean population. *PLoS One* [Internet] 2017;12(3):e0174642. Available from: <http://dx.doi.org/10.1371/journal.pone.0174642>
36. Sveinbjornsson G, Gudbjartsson DF, Halldorsson BV, et al. HLA class II sequence variants influence tuberculosis risk in populations of European ancestry. *Nat Genet* [Internet] 2016;48(3):318–22. Available from: <http://dx.doi.org/10.1038/ng.3498>
37. Tian C, Hromatka BS, Kiefer AK, et al. Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. *Nat Commun* [Internet] 2017;8(1):599. Available from: <http://dx.doi.org/10.1038/s41467-017-00257-5>
38. Sobota RS, Stein CM, Kodaman N, et al. A Locus at 5q33.3 Confers Resistance to Tuberculosis in Highly Susceptible Individuals. *Am J Hum Genet* [Internet] 2016;98(3):514–24. Available from: <http://dx.doi.org/10.1016/j.ajhg.2016.01.015>
39. Luo Y, Suliman S, Asgari S, et al. Early progression to active tuberculosis is a highly heritable trait driven by 3q23 in Peruvians. *Nat Commun* [Internet] 2019;10(1):3765. Available from: <http://dx.doi.org/10.1038/s41467-019-11664-1>
40. Quistrebart J, Orlova M, Kerner G, et al. Genome-wide association study of resistance to *Mycobacterium tuberculosis* infection identifies a locus at 10q26.2 in three distinct populations. *PLoS Genet* [Internet] 2021;17(3):e1009392. Available from: <http://dx.doi.org/10.1371/journal.pgen.1009392>
41. Zhou W, Nielsen JB, Fritsche LG, et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat Genet* [Internet] 2018 [cited 2022 Oct 19];50(9):1335–41. Available from: <https://www.nature.com/articles/s41588-018-0184-y>

Hamilton et al - IL-6 signalling and risk of TB disease


42. Reich D, Patterson N, Ramesh V, et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. *Am J Hum Genet* [Internet] 2007;80(4):716–26. Available from: <http://dx.doi.org/10.1086/513206>
43. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment Health* [Internet] 2019 [cited 2022 Oct 26];22(4):153–60. Available from: <https://ebmh.bmj.com/content/22/4/153>
44. Said S, Pazoki R, Karhunen V, et al. Genetic analysis of over half a million people characterises C-reactive protein loci. *Nat Commun* [Internet] 2022;13(1):2198. Available from: <http://dx.doi.org/10.1038/s41467-022-29650-5>
45. Khandaker GM, Zuber V, Rees JMB, et al. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. *Mol Psychiatry* [Internet] 2020;25(7):1477–86. Available from: <http://dx.doi.org/10.1038/s41380-019-0395-3>
46. Hamilton FW, Thomas M, Arnold D, et al. Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: Findings from a Mendelian randomisation study [Internet]. *PLoS Med*. 2023;(1):e1004174. Available from: <http://dx.doi.org/10.1371/journal.pmed.1004174>
47. Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. *Nature Reviews Methods Primers* [Internet] 2022 [cited 2022 Oct 14];2(1):1–21. Available from: <https://www.nature.com/articles/s43586-021-00092-5>
48. Cupido AJ, Asselbergs FW, Natarajan P, et al. Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R. *Br J Clin Pharmacol* [Internet] 2022;88(6):2875–84. Available from: <http://dx.doi.org/10.1111/bcp.15191>
49. Toshner M, Church C, Harbaum L, et al. Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. *Eur Respir J* [Internet] 2022;59(3). Available from: <http://dx.doi.org/10.1183/13993003.02463-2020>
50. Hamilton F, Mitchell R, Constantinescu A, et al. The effect of genetically proxied IL-6 signalling on severe malaria: A Mendelian randomisation analysis [Internet]. *bioRxiv*. 2022 [cited 2022 Nov 10];2022.11.04.22281934. Available from: <https://www.medrxiv.org/content/10.1101/2022.11.04.22281934v1.abstract>
51. Kappelmann N, Arloth J, Georgakis MK, et al. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. *JAMA Psychiatry* [Internet] 2021;78(2):161–70. Available from: <http://dx.doi.org/10.1001/jamapsychiatry.2020.3436>

Hamilton et al - IL-6 signalling and risk of TB disease

52. Thye T, Vannberg FO, Wong SH, et al. Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. *Nat Genet* [Internet] 2010;42(9):739–41. Available from: <http://dx.doi.org/10.1038/ng.639>
53. Daya M, van der Merwe L, Gignoux CR, van Helden PD, Möller M, Hoal EG. Using multi-way admixture mapping to elucidate TB susceptibility in the South African Coloured population. *BMC Genomics* [Internet] 2014;15:1021. Available from: <http://dx.doi.org/10.1186/1471-2164-15-1021>
54. Thye T, Owusu-Dabo E, Vannberg FO, et al. Common variants at 11p13 are associated with susceptibility to tuberculosis. *Nat Genet* [Internet] 2012;44(3):257–9. Available from: <http://dx.doi.org/10.1038/ng.1080>
55. Qi H, Zhang Y-B, Sun L, et al. Discovery of susceptibility loci associated with tuberculosis in Han Chinese. *Hum Mol Genet* [Internet] 2017;26(23):4752–63. Available from: <http://dx.doi.org/10.1093/hmg/ddx365>
56. Mahasirimongkol S, Yanai H, Mushiroda T, et al. Genome-wide association studies of tuberculosis in Asians identify distinct at-risk locus for young tuberculosis. *J Hum Genet* [Internet] 2012;57(6):363–7. Available from: <http://dx.doi.org/10.1038/jhg.2012.35>
57. Curtis J, Luo Y, Zenner HL, et al. Susceptibility to tuberculosis is associated with variants in the ASAP1 gene encoding a regulator of dendritic cell migration. *Nat Genet* [Internet] 2015;47(5):523–7. Available from: <http://dx.doi.org/10.1038/ng.3248>
58. Reay WR, Geaghan MP, 23andMe Research Team, Cairns MJ. The genetic architecture of pneumonia susceptibility implicates mucin biology and a relationship with psychiatric illness. *Nat Commun* [Internet] 2022;13(1):3756. Available from: <http://dx.doi.org/10.1038/s41467-022-31473-3>
59. Hou K, Ding Y, Xu Z, et al. Causal effects on complex traits are similar across segments of different continental ancestries within admixed individuals [Internet]. *medRxiv*. 2022 [cited 2022 Nov 3];2022.08.16.22278868. Available from: <https://www.medrxiv.org/content/10.1101/2022.08.16.22278868v1.abstract>
60. Wey EQ, Bristow C, Nandani A, et al. Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19 [Internet]. *bioRxiv*. 2021; Available from: <http://dx.doi.org/10.1101/2021.07.03.21259949>
61. Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. *BMJ* [Internet] 2018 [cited 2022 Nov 9];362. Available from: <https://www.bmj.com/content/362/bmj.k2738>

Hamilton et al - IL-6 signalling and risk of TB disease

Figure 1: Effect of altered IL-6 signalling activity on TB disease risk using Mendelian randomisation analyses. Odds ratios for the effect of reduced IL-6 signalling (on the scale of log CRP decrease) on TB disease. Estimates generated by the Wald ratio and use rs2228145 as a single instrumental variable. Odds ratios less than one suggest lower risk of TB disease.



Hamilton et al - tables

Table 1. Study populations included, TB case definitions, estimated TB prevalence and estimated TB exposure in controls. Adapted from Schurz et al. TB prevalence and estimated exposure could not be derived for additional registries and studies not part of International TB Host genetics Consortium (N/A = not available).

Study / Dataset	TB case definition	Population	Cases / Controls	TB prevalence / 100 000 p.a.	Estimated proportion of controls ever exposed to Mtb (±SD)
Studies from International TB Host genetics Consortium					
China 1 (unpublished)	Acid-fast staining and culturing of Mtb from sputum samples	Asian	483 / 587	89	0.302 (0.101)
China 2 (unpublished)	Acid-fast staining and culturing of Mtb from sputum samples	Asian	1290 / 1145	89	0.302 (0.101)
China 3 Qi et al, 2017	Acid-fast staining and culturing of Mtb from sputum samples	Asian	972 / 1537	89	0.302 (0.101)
Thailand - Mahasirimongkol et al 2012	Acid-fast staining and culturing of Mtb from sputum samples	Asian	433 / 295	236	0.404 (0.112)
Japan Mahasirimongkol et al 2012	Acid-fast staining and culturing of Mtb from sputum samples.	Asian	751 / 3199	23	0.142 (0.125)
Russia Curtis et al 2015	Acid-fast staining and culturing of Mtb from sputum samples.	European	5914 / 6022	109	0.191 (0.093)
Estonia (unpublished)	Biobank TB cases	European	62 / 2660	13	0.116 (0.093)
Germany (unpublished)	Not available	European	586 / 333	7.8	0.067 (0.081)
Gambia WTCCC	Not available	African	1316 / 1382	126	0.280 (0.089)
Ghana Thye et al	Acid-fast staining and culturing of Mtb from sputum samples	African	1359 / 1952	282	0.539 (0.198)
SAC(A)^ Daya et al	Acid-fast staining and culturing of Mtb from sputum samples	African	642 / 91	717	0.436 (0.127)
SAC(M)* Schurz et al	Acid-fast staining and culturing of Mtb from sputum samples	African	410 / 405	717	0.436 (0.127)
Additional data sources not included in International TB Host genetics consortium					
UK Biobank	Self-report of tuberculosis	European	2,046 / 418,427	N/A	N/A
FinnGen	ICD A15 (Respiratory confirmed tuberculosis)	European	401 / 321,302	N/A	N/A
Biobank Japan	ICD A15-16 (Respiratory tuberculosis)	Asian	549 / 211,904	N/A	N/A
Zheng et al	Microbiological and clinical diagnosis	Asian	833 / 1220	N/A	N/A

Hamilton et al - tables

Table 2: Associations of the rs2228145-C SNP in each GWAS and meta-analysed results

Study	Odds ratio	Standard Error	C allele frequency	P value
South Africa, Daya et al	0.991	0.2342	0.2217	0.9692
South Africa, Schurz et al	0.9184	0.147	0.1587	0.5626
China 1 (unpublished)	0.9289	0.1306	0.4247	0.5722
China 2 (unpublished)	0.9592	0.0599	0.4205	0.4868
China, Qi et al	0.8641	0.0606	0.4135	0.016
Estonia (unpublished)	1.1707	0.098	0.3256	0.9372
Gambia (WTCCC)	1.2302	0.1032	0.0905	0.0447
Germany (unpublished)	1.0051	0.1041	0.383	0.961
Ghana, Thye et al	1.0817	0.0876	0.0923	0.3698
Japan, Mahasirimongkol et al	0.9194	0.062	0.603	0.1729
Russia, Curtis et al	0.907	0.0287	0.3253	0.0007
Finland, FinnGen	0.8718	0.0875	0.298	0.117
Japan, BBJ	0.9067	0.0617	0.3928	0.1125
China, Zheng et al	1.011	0.069	NA	0.87
UK, UKBiobank	0.9173	0.0319	0.39	0.0069
Thailand, Mahasirimongkol et al	0.9996	0.0439	0.7652	0.9929
Meta-analysis (FE)	0.9405	0.0147	-	2.92 x 10⁻⁰⁵
Meta-analysis (RE)	0.950	0.0194	-	0.0088